[待翻譯] Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

金融

[待翻譯] Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

[AI 翻譯暫時失敗，請人工確認] Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

CNBC 10月20日 20:50 1 分鐘閱讀

來源署名

本文為 AI 輔助中文翻譯與整理，內容依據原文來源： CNBC

這篇新聞正在等待 AI 完整中文翻譯。請先閱讀摘要與原文來源。

[待翻譯] Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

相關新聞

[待翻譯] Looking for AI stocks that are still cheap? Consider these two under-the-radar picks.

[待翻譯] It’s no secret what the best financial advice for retirement is — but most people ignore it anyway

[待翻譯] Myriad Genetics stock surges on $210M prenatal unit sale

[待翻譯] Morocco stocks lower at close of trade; Moroccan All Shares down 0.07%

[待翻譯] Oil falls more than 2% after unconfirmed report of ’middle ground’ U.S.-Iran deal

[待翻譯] Starboard’s Smith unveils stake in Solstice, presses for improvements